Detalhe da pesquisa
1.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Blood
; 137(3): 323-335, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32967009
2.
A novel GAB2::BRAF fusion in cutaneous non-Langerhans-cell histiocytosis with systemic involvement.
J Cutan Pathol
; 49(8): 727-730, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332933
3.
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
Blood Adv
; 8(2): 453-467, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903325
4.
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
Blood Adv
; 7(22): 6990-7005, 2023 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774014
5.
Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
Leuk Lymphoma
; 62(14): 3333-3347, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34402732